motesanib + panitumumab + FOLFOX4

This is an **experimental combination therapy** consisting of: - **Motesanib:** a small molecule **multikinase inhibitor** that targets vascular endothelial growth factor receptors (VEGFR 1, 2, 3), platelet-derived growth factor receptor (PDGFR), and c-Kit to inhibit angiogenesis and tumor growth. - **Panitumumab:** a fully human **monoclonal antibody** that binds the **epidermal growth factor receptor (EGFR)** and prevents EGFR-mediated signaling, thus blocking cell growth and proliferation, developed primarily for metastatic colorectal cancer. - **FOLFOX4 regimen:** is a standard intravenous **chemotherapy combination** for colorectal cancer, comprising **folinic acid (leucovorin)**, **fluorouracil (5-FU)**, and **oxaliplatin**. These agents act as antimetabolites and DNA cross-linkers and are cytotoxic to cancer cells[1][3][4]. Used in combination, this regimen aims to target colorectal cancer cells via **multiple complementary mechanisms**: blocking angiogenesis (motesanib), inhibiting EGFR signaling (panitumumab), and directly damaging DNA and interfering with nucleotide synthesis (FOLFOX4 constituents).

Other names

motesanibAMG 706AMG706AMG-706panitumumabABX-EGFfolinic acidleucovorinfluorouracil5-FUoxaliplatinEloxatin